Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Oruka Therapeutics, Inc.

Clinicaltrial registered12 Nov 2026

Oruka Therapeutics, Inc.

12 Nov 2026: Trial registered · An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis
Conditions
Plaque Psoriasis
Phase
Phase 2
Study Type
Interventional
Status
Enrolling By Invitation
Countries
United States, Canada
Country
United States
Reference
NCT07933783
Location
United States, Canada
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Oruka Therapeutics, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.